Ziming Wu

Title: Ziming Wu: Innovator in Cancer Research

Introduction

Ziming Wu is a prominent inventor based in Beijing, China. He has made significant contributions to the field of cancer research through his innovative patent work. His expertise lies in the development of advanced techniques for tumor analysis and treatment.

Latest Patents

Ziming Wu holds a patent for the LRFFT2 cell. This patent involves using human peripheral blood for circulating tumor DNA (ctDNA) sequencing or tumor tissues for whole exome sequencing. The process screens for mutation sites to perform antigen epitope prediction and synthesizes an expression gene sequence of mutant peptides. Additionally, the patent describes constructing a lentiviral vector, packaging the lentivirus, and transfecting antigen-presenting cells (APCs) to transform specific LV cells. The method includes co-culturing with peripheral blood mononuclear cells (PBMC) to screen for effective polypeptides and transform common T cells into RFF cells. The suppressive signaling molecules involved include PD-1, Tim-3, LAG3, CTLA-4, BTLA, VISTA, CD160, and 2B4 (CD244). Antigen-presenting cells utilized in this process include PBMC, dendritic cells, neutrophils, B lymphocytes, and macrophages.

Career Highlights

Ziming Wu has worked with Beijing Dcty Biotech Co., Ltd., where he has contributed to various research projects. His work has focused on enhancing cancer treatment methodologies and improving patient outcomes through innovative technologies.

Collaborations

Ziming Wu has collaborated with notable colleagues such as Shunchang Jiao and Rong Zhang. Their combined efforts have advanced the research and development of cancer therapies.

Conclusion

Ziming Wu is a key figure in the field of cancer research, with a focus on innovative solutions for tumor analysis and treatment. His contributions through patents and collaborations continue to impact the scientific community positively.